Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432716 · ClinicalTrials.gov registry record · Phase 1
Investigation of the Safety of Intranasal Glulisine in Down Syndrome
A Phase 1 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02432716: Completed Phase 1 study, sponsored by HealthPartners Institute.
NCT02432716 is a Phase 1 study that has completed, run by HealthPartners Institute. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432716, a Phase 1 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is a single center, randomized, double-blind, placebo-controlled, cross-over pilot study designed to assess the safety of intranasally (IN) delivered glulisine versus placebo in patients with DS. Subjects will be randomized into this cross-over study and within subject comparisons conducted between single treatment of intranasal insulin glulisine and single treatment of intranasal placebo. All subjects will also receive a single treatment of placebo prior to randomization to ensure adherence to study procedures.
Primary Outcome
Number of adverse and/or serious events
Interventions
- DRUG Saline
- DRUG Insulin glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-10-18 |
| Phase | Phase 1 |
What the finished NCT02432716 record still lists
NCT02432716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02432716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02432716 about?
NCT02432716 is a clinical study titled "Investigation of the Safety of Intranasal Glulisine in Down Syndrome". This study is a single center, randomized, double-blind, placebo-controlled, cross-over pilot study designed to assess the safety of intranasally (IN) delivered glulisine versus placebo in patients with DS. Subjects will be randomized into this cross-over study and within subject comparisons conduct...
What is the current status of trial NCT02432716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-04. Estimated completion is 2018-10-18.
What interventions are being tested in trial NCT02432716?
The interventions under investigation include: Saline (DRUG), Insulin glulisine (DRUG).
Who is sponsoring clinical trial NCT02432716?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02432716's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia